We are live on ! Find out more
AMLX icon

Amylyx Pharmaceuticals
AMLX

147 hedge funds and large institutions have $1.51B invested in Amylyx Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 38 funds opening new positions, 60 increasing their positions, 36 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

79% more call options, than puts

Call options by funds: $56.4M | Put options by funds: $31.4M

67% more repeat investments, than reductions

Existing positions increased: 60 | Existing positions reduced: 36

58% more first-time investments, than exits

New positions opened: 38 | Existing positions closed: 24

11% more funds holding

Funds holding: 133 → 147 (+14)

3.69% more ownership

Funds ownership: 73.31% → 77% (+3.7%)

0% more funds holding in top 10

Funds holding in top 10: 5 → 5 (0)

16% less capital invested

Capital invested by funds: $1.79B → $1.51B (-$286M)

Holders
147
Holders Change
+14
Holders Change %
+10.53%
% of All Funds
2.34%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.08%
New
38
Increased
60
Reduced
36
Closed
24
Calls
$56.4M
Puts
$31.4M
Net Calls
+$25M
Net Calls Change
+$35.6M

Top Buyers

Rank Fund Capital Flow
1
Marshall Wace
Marshall Wace
United Kingdom
+$39.6M
2
APM
Avidity Partners Management
Texas
+$31.3M
3
O
OrbiMed
New York
+$28.3M
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$22.2M
5
GPP
Great Point Partners
Connecticut
+$20.6M

Top Sellers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$62.6M
2
Viking Global Investors
Viking Global Investors
Connecticut
-$58.1M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$31.3M
4
DM
Deerfield Management
New York
-$24.6M
5
CAM
Cormorant Asset Management
Massachusetts
-$20.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
MS
51
Maven Securities
Jersey
$2.93M -$1.74M -50,000 -33%
TCM
52
Tang Capital Management
California
$2.93M – – –
HF
53
HRT Financial
New York
$2.75M +$3.26M +93,790 New
Norges Bank
54
Norges Bank
Norway
$2.7M +$372K +10,700 +13%
Squarepoint
55
Squarepoint
New York
$2.69M +$1.8M +51,726 +129%
Barclays
56
Barclays
United Kingdom
$2.4M +$1.51M +43,411 +113%
RhumbLine Advisers
57
RhumbLine Advisers
Massachusetts
$2.23M +$153K +4,398 +6%
SEI Investments
58
SEI Investments
Pennsylvania
$2.04M +$1.94M +55,888 +406%
Bank of America
59
Bank of America
North Carolina
$2M +$172K +4,958 +8%
JGC
60
J. Goldman & Co
New York
$2M +$786K +22,636 +50%
CSS
61
Cubist Systematic Strategies
Connecticut
$1.88M +$2.09M +60,192 +1,582%
SCM
62
Soleus Capital Management
Connecticut
$1.85M +$437K +12,578 +25%
OAM
63
Oberweis Asset Management
Illinois
$1.77M +$2.1M +60,305 New
WMSA
64
Weiss Multi-Strategy Advisers
New York
$1.59M +$1.88M +54,054 New
AllianceBernstein
65
AllianceBernstein
Tennessee
$1.51M +$532K +15,300 +42%
Mariner
66
Mariner
Kansas
$1.43M +$369K +10,614 +28%
PI
67
Putnam Investments
Massachusetts
$1.42M +$879K +25,289 +110%
UBS Group
68
UBS Group
Switzerland
$1.37M +$1.5M +43,076 +1,239%
AA
69
ALPS Advisors
Colorado
$1.28M -$43.6K -1,256 -3%
Tudor Investment Corp
70
Tudor Investment Corp
Connecticut
$1.1M +$54.4K +1,567 +4%
Citigroup
71
Citigroup
New York
$972K +$813K +23,403 +241%
Qube Research & Technologies (QRT)
72
Qube Research & Technologies (QRT)
United Kingdom
$931K +$1.1M +31,725 New
Deutsche Bank
73
Deutsche Bank
Germany
$919K +$325K +9,359 +43%
DekaBank Deutsche Girozentrale
74
DekaBank Deutsche Girozentrale
Germany
$914K +$1.15M +33,000 New
DTL
75
Dynamic Technology Lab
Singapore
$906K +$1.07M +30,857 New
1 2
3
4 5

AMLX Hedge Fund Activity: Q1 2023 in Review

147 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Amylyx Pharmaceuticals (AMLX) for Q1 2023, worth a combined $1.51B — down 16% from $1.79B a quarter earlier.

Buyers outnumbered sellers: 38 funds opened new AMLX positions and 24 closed out — a net gain of 14 holders — while 60 added to existing stakes and 36 trimmed.

The largest buyer was Marshall Wace, opening a new position worth an estimated $39.6M. The largest seller was Point72 Asset Management, cutting an estimated $62.6M.

  • 147 institutional investors held Amylyx Pharmaceuticals (AMLX) as of Q1 2023, up from 133 in Q4 2022.
  • Funds reported $1.51B of Amylyx Pharmaceuticals stock for Q1 2023, down 16% quarter-over-quarter.
  • 38 funds opened new Amylyx Pharmaceuticals positions in Q1 2023 and 24 closed out, a net change of +14 holders.
  • The largest Amylyx Pharmaceuticals buyer in Q1 2023 was Marshall Wace, an estimated $39.6M added.
  • The largest Amylyx Pharmaceuticals seller in Q1 2023 was Point72 Asset Management, an estimated $62.6M sold.

Based on aggregated 13F filings for Q1 2023.